Sub Banner Image

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Market Impact

Vandana Singh

·

September 8, 2025

·

Benzinga

Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds.

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.